Tabelecleucel (Ebvallo) for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD)
The FDA is expected to decide on Tabelecleucel for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in an undisclosed window, under a BLA resubmission from Pierre Fabre Pharmaceuticals / Atara Biotherapeutics.
What is being decided
Pierre Fabre Pharmaceuticals / Atara Biotherapeutics has a BLA resubmission under FDA review for Tabelecleucel (Ebvallo) in Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). Off-the-shelf T cell therapy made from healthy donors' EBV-specific T cells, for adults and children 2 and older whose EBV+ PTLD has come back or not responded after at least one prior therapy. PTLD is an ultra-rare cancer that follows a solid organ or stem cell transplant; once first-line treatment fails, median survival is about 3 weeks after a stem cell transplant and 4 months after an organ transplant. This is the third time the application has gone to the FDA: a January 2025 complete response letter cited a third-party manufacturing site, and a January 2026 letter said the single-arm ALLELE trial could no longer support accelerated approval. Pierre Fabre resubmitted on September 30, 2026 with more patients and longer follow-up from ALLELE plus expanded access and European commercial data, after an April 2026 Type A meeting. The FDA has not yet said whether it has accepted the resubmission, and no target action date has been disclosed. Already approved in the EU, UK and Switzerland as Ebvallo.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Frequently asked questions
When will the FDA decide on Tabelecleucel?
Pierre Fabre Pharmaceuticals / Atara Biotherapeutics has disclosed a decision window of later this cycle for Tabelecleucel in Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), without an exact date.
What is Tabelecleucel being reviewed for?
Pierre Fabre Pharmaceuticals / Atara Biotherapeutics submitted a BLA resubmission for Tabelecleucel in Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). Off-the-shelf T cell therapy made from healthy donors' EBV-specific T cells, for adults and children 2 and older whose EBV+ PTLD has come back or not responded after at least one prior therapy. PTLD is an ultra-rare cancer that follows a solid organ or stem cell transplant; once first-line treatment fails, median survival is about 3 weeks after a stem cell transplant and 4 months after an organ transplant. This is the third time the application has gone to the FDA: a January 2025 complete response letter cited a third-party manufacturing site, and a January 2026 letter said the single-arm ALLELE trial could no longer support accelerated approval. Pierre Fabre resubmitted on September 30, 2026 with more patients and longer follow-up from ALLELE plus expanded access and European commercial data, after an April 2026 Type A meeting. The FDA has not yet said whether it has accepted the resubmission, and no target action date has been disclosed. Already approved in the EU, UK and Switzerland as Ebvallo.
What happens after the Tabelecleucel decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Pierre Fabre Pharmaceuticals press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.